ϩ cytotoxic T lymphocytes (CTLs) are crucial for elimination of the infection (2, 7, 13, 18). CD8
Infection of mice with the arenavirus lymphocytic choriomeningitis virus (LCMV) results in a vigorous antiviral immune response, in which CD8
ϩ cytotoxic T lymphocytes (CTLs) are crucial for elimination of the infection (2, 7, 13, 18) . CD8
ϩ CTLs recognize short antigenic peptides associated with major histocompatibility complex (MHC) class I molecules. In BALB/c mice, the primary antiviral CTL response is almost exclusively directed against a single peptide from the LCMV nucleoprotein (NP) (residues 118 to 126 [NP [118] [119] [120] [121] [122] [123] [124] [125] [126] -restricted responses are usually detected (5, 10, 21) , and the response against the L d -restricted NP 118-126 epitope is therefore considered immunodominant. However, the lack of detectable dm2 (which will be referred to as "dm2") has a deletion in the gene for the L d class I molecule (17, 24, 28) 
MATERIALS AND METHODS
Mice. Five-to eight-week-old female BALB/c mice were purchased from The Jackson Laboratory (Bar Harbor, Maine) or bred at our colony at the University of California at Los Angeles. BALB/c-H-2 dm2 mice (dm2 mice) were bred at our colony at the University of California at Los Angeles. (4) and its derivative clone 13 were used in this study (1, 4, 16 Adoptive transfer. dm2 mice were irradiated (550 to 600 rads) 1 day before transfer. Single-cell suspensions of splenocytes (5 ϫ 10 7 cells) from LCMV Armstrong-infected BALB/c mice were transferred into irradiated dm2 mice by i.v. injection. Recipient mice were simultaneously infected i.v. with LCMV clone 13. Mice were sacrificed at day 8 after the transfer and rechallenge, and singlecell suspensions of splenocytes were used in 51 Cr release assays to measure cytotoxic activity.
Virus and cells. LCMV Armstrong
Peptides. Peptides were either synthesized at Cytel as previously described (25) or purchased as crude material from Chiron Mimotopes (San Diego, Calif.). Peptides synthesized at Cytel were purified to Ͼ95% homogeneity by reversephase high-performance liquid chromatography. The purity of the synthetic peptides was assayed on an analytical reverse-phase column, and their composition was ascertained by amino acid analysis, sequencing, and/or mass spectrometry analysis.
CTL assay. Cytotoxic activities of effector cells were tested in a standard 6-h 51 Cr release assay. Single-cell suspensions of splenocytes were used as effectors. The assay was done with RPMI medium supplemented with 10% fetal bovine serum 4 mM L-glutamine, 50 M ␤-mercaptoethanol, and antibiotics. Target cells either were infected with LCMV clone 13 at a multiplicity of infection of 1 at 24 h before the assay or were coated with peptide (1 g/ml) for 1 h at 37°C. The percentage of specific lysis was calculated as 100 ϫ [(sample release Ϫ spontaneous release)/(total release Ϫ spontaneous release)].
RESULTS

BALB/c donor splenocytes generate a protective antiviral CTL response upon transfer into irradiated dm2 mice.
The experimental model used in this study is based on the transfer of splenocytes from acutely infected BALB/c mice into irradiated dm2 mice, followed by an LCMV challenge with clone 13. To obtain donor spleen cells, BALB/c mice were first infected with 2 ϫ 10 5 PFU of LCMV Armstrong. This infection induces a potent antiviral CTL response that is largely directed against the dominant NP 118-126 epitope. At day 8 postinfection, 5 ϫ 10 7 splenocytes from LCMV-infected BALB/c mice were injected i.v. into irradiated dm2 mice; at the same time, the recipient mice were challenged with 2 ϫ 10 6 PFU of LCMV clone 13. LCMV clone 13 is an LCMV Armstrong derivative that readily establishes a persistent infection in mice, unless primed LCMV-specific CD8 ϩ CTL precursors (CTLps) are present (3, 4, 14, 15) . Thus, naive mice cannot control this challenge. First, we asked whether the LCMV-primed BALB/c donor CTLs would be able to protect the recipients against the LCMV clone 13 challenge. We determined virus titers in serum and in the spleens of the recipient mice at day 8 after transfer and LCMV challenge. The results clearly show that recipient mice controlled the LCMV infection (Table 1) . Since CD8 ϩ CTLs are critical for viral clearance (2, 7, 13, 18) , this result implies that the donor CD8 ϩ T cells in the irradiated recipient dm2 mice were capable of mounting an effective antiviral CTL response. Control dm2 mice that were irradiated but had not received donor spleen tissue did not clear the infection, proving that the protection was completely dependent on the BALB/c donor spleen cells. Similar results were obtained with irradiated BALB/c recipients: only the mice that received donor spleen tissue could control the LCMV infection. Transfer of splenocytes from naive BALB/c mice into either BALB/c or dm2 mice did not protect the recipients against chronic infection (reference 4 and data not shown), demonstrating that primed CTLs are required for protection. ) cells was negligible (Fig. 1A) . Splenocytes from these BALB/c mice were transferred into irradiated dm2 mice, which were then challenged with LCMV clone 13. The LCMV infection induced a potent secondary CTL response from the donor splenocytes. Direct ex vivo analysis of antiviral CTL responses in the recipients at day 8 after transfer and rechallenge revealed that the donor CTLs recognized epitopes presented by LCMV-infected BALB clone 7 and dm2 cells but no longer lysed infected L cells that presented the L d -restricted immunodominant epitope (Fig. 1B) (Fig. 1C) , confirming previous observations (10) . This CTL response is relatively weak, consistent with several studies that indicate that dm2 mice eliminate virus less rapidly (10) , are more susceptible to establishment of chronic infection (19) , and are less susceptible to T-cell-mediated immunopathology (5) . Finally, when BALB/c effectors are transferred into irradiated BALB/c mice and rechallenged with LCMV, the antiviral CTL response is, as expected, L d restricted (data not shown).
The antiviral CTL response is directed against a subdominant, K d -restricted epitope in the viral glycoprotein. We have -restricted epitopes, it seemed plausible that one or more of the K d binding peptides were in fact new epitopes in the adoptive transfer model. To verify this, we studied whether any of these peptides could sensitize target cells for lysis by BALB/c effectors after their transfer and secondary stimulation in dm2 mice. In an experimental setup similar to the one described above, irradiated dm2 mice received 5 ϫ 10 7 splenocytes from LCMV-infected BALB/c mice and were inoculated with LCMV clone 13. At day 8 postinfection, the recipient mice were sacrificed and the spleen cells (Fig. 2B) . Instead, peptide GP 283-291 efficiently sensitized targets for lysis (Fig. 2B) . Peptide GP 283-291 (GYCLTKWMI) is a K d -restricted epitope derived from the viral GP, and in our previous study, it was identified as a subdominant LCMV epitope (see Discussion). Weak responses against GP 99-108 could sometimes be detected. When primary antiviral responses are monitored in dm2 mice without transfer and irradiation, GP 283-291 is also the dominant epitope (Fig. 2C) . ϩ CTLps, mice cannot control the strong LCMV clone 13 challenge used in this study. After transfer into dm2 mice and antigenic (re)stimulation, they expanded to levels that were readily detectable in our assays. One of the new K (10) . Here, we confirm these previous findings and extend them by identifying one of the major epitopes in dm2 mice. However, Gegin and Lehmann-Grube also observed that transfer of LCMV-specific CTLs (mostly L d restricted) from BALB/c mice into dm2 mutant mice resulted in viral clearance from dm2 mice in the absence of any
DISCUSSION
-restricted CTL effectors and they concluded that killing per se was not essential for clearance of LCMV infection (10) . Our study shows very clearly that subdominant CTL effectors are substantially enhanced and readily detectable in this adoptive transfer model. These different results could be due to the fact that in our study, the recipient dm2 mice were infected with 2 ϫ 10 6 PFU of LCMV clone 13, which provides a much stronger antigenic stimulation than the challenge used by Gegin and Lehmann-Grube (10 3 PFU of LCMV WE). In addition, we analyzed antiviral CTL responses at day 8 after transfer, whereas Gegin and Lehmann-Grube measured CTL responses at 48 h after transfer (10) .
In were primed by LCMV in BALB/c mice. As shown previously, GP 283-291 -specific CTLs could also be primed by peptide immunization (30) . GP 283-291 -specific CTLs appear to be (at least in part) responsible for viral clearance in dm2 mice (this study) and provide protection against an LCMV challenge after peptide immunization (30) . These findings are particularly interesting in the light of future studies of therapeutic vaccination, i.e., immunization to fight an established, chronic infection. One of the most striking characteristics of a chronic LCMV infection is that the antiviral CD8 ϩ CTLs disappear before the virus is cleared (4, 6, 20, 29) . This is thought to result (in part) from the exhaustion (deletion) of LCMV-specific CTLs: massive antigenic stimulation activates all virus-specific CTLs, leading to anergy and death of these CTLs (12, 20) . Because subdominant epitopes do not play a major role in the primary response in BALB/c mice ( Fig. 2A) , immunization with a subdominant epitope, such as GP 283-291 , might be used to trigger a new antiviral response in chronically infected animals.
Our data show that in the absence of the MHC class I molecule that presents the immunodominant epitope, the anti-LCMV CTL response can be "forced" towards different epitopes. The plasticity of the H-2 d -restricted antiviral CTL response has also been demonstrated by von Herrath et al., who developed transgenic mice expressing the LCMV NP gene in the thymus (31) . These mice did not generate any highaffinity NP-specific CTLs but instead generated a weak H-2 d -restricted antiviral CTL response to one or more epitopes in the N-terminal part of the viral GP. It would be interesting to analyze CTL responses against our set of peptides in the transgenic mouse model.
In conclusion, our data demonstrate that in vivo activation of subdominant LCMV epitopes can occur, that CTLs directed against these epitopes are capable of controlling infection, and that epitopes that were previously subdominant can become dominant under different experimental conditions or in a different cellular environment.
